261 related articles for article (PubMed ID: 25203609)
1. Evaluation of antitumor effect of zoledronic acid entrapped in folate-linked liposome for targeting to tumor-associated macrophages.
Hattori Y; Yamashita J; Sakaida C; Kawano K; Yonemochi E
J Liposome Res; 2015; 25(2):131-40. PubMed ID: 25203609
[TBL] [Abstract][Full Text] [Related]
2. Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity.
Shmeeda H; Amitay Y; Tzemach D; Gorin J; Gabizon A
J Control Release; 2013 May; 167(3):265-75. PubMed ID: 23419948
[TBL] [Abstract][Full Text] [Related]
3. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study.
Marra M; Salzano G; Leonetti C; Porru M; Franco R; Zappavigna S; Liguori G; Botti G; Chieffi P; Lamberti M; Vitale G; Abbruzzese A; La Rotonda MI; De Rosa G; Caraglia M
Biotechnol Adv; 2012; 30(1):302-9. PubMed ID: 21741464
[TBL] [Abstract][Full Text] [Related]
4. Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells.
Shmeeda H; Amitay Y; Gorin J; Tzemach D; Mak L; Ogorka J; Kumar S; Zhang JA; Gabizon A
J Control Release; 2010 Aug; 146(1):76-83. PubMed ID: 20462513
[TBL] [Abstract][Full Text] [Related]
5. 7-acetoxycoumarin dimer-incorporated and folate-decorated liposomes: photoresponsive release and in vitro targeting and efficacy.
Seo HJ; Kim JC
Bioconjug Chem; 2014 Mar; 25(3):533-42. PubMed ID: 24533729
[TBL] [Abstract][Full Text] [Related]
6. Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic.
Au KM; Satterlee A; Min Y; Tian X; Kim YS; Caster JM; Zhang L; Zhang T; Huang L; Wang AZ
Biomaterials; 2016 Mar; 82():178-93. PubMed ID: 26763733
[TBL] [Abstract][Full Text] [Related]
7. Efficient delivery of an antisense oligodeoxyribonucleotide formulated in folate receptor-targeted liposomes.
Chiu SJ; Marcucci G; Lee RJ
Anticancer Res; 2006; 26(2A):1049-56. PubMed ID: 16619505
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid enhances antitumor efficacy of liposomal doxorubicin.
Hattori Y; Shibuya K; Kojima K; Miatmoko A; Kawano K; Ozaki K; Yonemochi E
Int J Oncol; 2015 Jul; 47(1):211-9. PubMed ID: 25955490
[TBL] [Abstract][Full Text] [Related]
9. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity.
Patil Y; Amitay Y; Ohana P; Shmeeda H; Gabizon A
J Control Release; 2016 Mar; 225():87-95. PubMed ID: 26809007
[TBL] [Abstract][Full Text] [Related]
10. Higher liposomal membrane fluidity enhances the in vitro antitumor activity of folate-targeted liposomal mitoxantrone.
Kawano K; Onose E; Hattori Y; Maitani Y
Mol Pharm; 2009; 6(1):98-104. PubMed ID: 19072653
[TBL] [Abstract][Full Text] [Related]
11. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model.
Pan XQ; Wang H; Lee RJ
Pharm Res; 2003 Mar; 20(3):417-22. PubMed ID: 12669962
[TBL] [Abstract][Full Text] [Related]
13. Preparation and in vitro evaluation of a folate-linked liposomal curcumin formulation.
Lu Y; Ding N; Yang C; Huang L; Liu J; Xiang G
J Liposome Res; 2012 Jun; 22(2):110-9. PubMed ID: 22372871
[TBL] [Abstract][Full Text] [Related]
14. Folate-appended β-cyclodextrin as a promising tumor targeting carrier for antitumor drugs in vitro and in vivo.
Okamatsu A; Motoyama K; Onodera R; Higashi T; Koshigoe T; Shimada Y; Hattori K; Takeuchi T; Arima H
Bioconjug Chem; 2013 Apr; 24(4):724-33. PubMed ID: 23458386
[TBL] [Abstract][Full Text] [Related]
15. Effect of polyethylene glycol linker chain length of folate-linked microemulsions loading aclacinomycin A on targeting ability and antitumor effect in vitro and in vivo.
Shiokawa T; Hattori Y; Kawano K; Ohguchi Y; Kawakami H; Toma K; Maitani Y
Clin Cancer Res; 2005 Mar; 11(5):2018-25. PubMed ID: 15756028
[TBL] [Abstract][Full Text] [Related]
16. Targeting folate receptor β positive tumor-associated macrophages in lung cancer with a folate-modified liposomal complex.
Tie Y; Zheng H; He Z; Yang J; Shao B; Liu L; Luo M; Yuan X; Liu Y; Zhang X; Li H; Wu M; Wei X
Signal Transduct Target Ther; 2020 Jan; 5(1):6. PubMed ID: 32296026
[TBL] [Abstract][Full Text] [Related]
17. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
[TBL] [Abstract][Full Text] [Related]
18. Liposome encapsulated zoledronate favours M1-like behaviour in murine macrophages cultured with soluble factors from breast cancer cells.
Sousa S; Auriola S; Mönkkönen J; Määttä J
BMC Cancer; 2015 Jan; 15():4. PubMed ID: 25588705
[TBL] [Abstract][Full Text] [Related]
19. Design of folate-linked liposomal doxorubicin to its antitumor effect in mice.
Yamada A; Taniguchi Y; Kawano K; Honda T; Hattori Y; Maitani Y
Clin Cancer Res; 2008 Dec; 14(24):8161-8. PubMed ID: 19088031
[TBL] [Abstract][Full Text] [Related]
20. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
